» Articles » PMID: 3793280

A Haemodynamic Study of the Effects of Combined Slow-calcium Channel Blockade (nisoldipine) and Beta-blockade (metoprolol) in Coronary Heart Disease

Overview
Journal Int J Cardiol
Publisher Elsevier
Date 1986 Nov 1
PMID 3793280
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The interaction of a new slow-calcium blocker (nisoldipine) and the beta-blocker metoprolol was evaluated in 16 patients with stable angina. Haemodynamic parameters were determined in a control rest and exercise period. Patients were then randomised equally to nisoldipine (4-8 micrograms/kg) or metoprolol (10 mg) and the haemodynamics of monotherapy assessed; finally the second drug was administered and the effects of combination determined. At rest nisoldipine reduced systemic blood pressure and vascular resistance (P less than 0.01); heart rate, cardiac and stroke volume indices increased (P less than 0.01) at an unchanged pulmonary artery occluded pressure. Metoprolol alone reduced heart rate (P less than 0.05) and increased the pulmonary artery occluded pressure (P less than 0.05). Combination therapy reduced systemic blood pressure and vascular resistance (P less than 0.01); cardiac index and pulmonary artery occluded pressure increased (P less than 0.01) at an unchanged heart rate. The effect of combination was influenced by the order of administration; an improvement in cardiac performance was particularly evident when nisoldipine was added to metoprolol. The interaction during dynamic exercise was similar to that at rest. Thus these data indicated the haemodynamic safety of concurrent nisoldipine/metoprolol therapy; the addition of nisoldipine to metoprolol appeared to offset in part the cardiodepressant properties of beta-blockade.

Citing Articles

Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol.

Gulati G, Lagethon Heck S, Ree A, Hoffmann P, Schulz-Menger J, Fagerland M Eur Heart J. 2016; 37(21):1671-80.

PMID: 26903532 PMC: 4887703. DOI: 10.1093/eurheartj/ehw022.


The pharmacology of nisoldipine.

Knorr A Cardiovasc Drugs Ther. 1987; 1(4):393-402.

PMID: 3154674 DOI: 10.1007/BF02209081.


Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Friedel H, Sorkin E Drugs. 1988; 36(6):682-731.

PMID: 3065058 DOI: 10.2165/00003495-198836060-00003.


Hemodynamic interactions of a new beta blocker, celiprolol, with nifedipine in angina pectoris.

Silke B, Verma S, Guy S Cardiovasc Drugs Ther. 1991; 5(4):681-7.

PMID: 1679661 DOI: 10.1007/BF03029741.


Cardiovascular effects of the novel potassium channel opener bimakalim in conscious pigs after myocardial infarction: a comparative study with nicorandil.

van Woerkens L, Baas N, van der Giessen W, Verdouw P Cardiovasc Drugs Ther. 1992; 6(4):409-17.

PMID: 1387797 DOI: 10.1007/BF00054190.